Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx (Nasdaq: CDNA) reported preliminary, unaudited results for Q4 and full year 2025. Q4 revenue ~ $108M (+25% YoY) with testing services revenue ~ $78M (+23% YoY) and testing volume ~ 53,000 (+17% YoY). FY2025 revenue ~ $380M (+14% YoY) with testing services ~ $274M (+10% YoY), testing volume ~ 200,000 (+14% YoY), patient & digital solutions ~ $57M (+31% YoY) and product revenue ~ $48M (+19% YoY).
Average revenue per test ~ $1,470 (includes ~ $5M prior period revenue). cash, cash equivalents and marketable securities ~ $200M at 12/31/2025. Share repurchases: $12M in Q4 (773,000 shares) and $88M for year (5.8M shares) at average prices shown. Results are preliminary and may change after audit.
CareDx (Nasdaq: CDNA) and 10x Genomics (Nasdaq: TXG) launched ImmuneScape, a multiomics research program to map immune biology in transplant rejection and therapeutic response.
The collaboration will use 10x Xenium spatial and Chromium Flex single cell platforms to profile FFPE biopsy samples at cellular resolution, focusing on antibody-mediated rejection (AMR) and microvascular inflammation (MVI). Insights are intended to support future diagnostic development and to correlate tissue-level immune architecture with clinical outcomes, including response to anti-CD38 therapies.
CareDx (Nasdaq: CDNA) announced inducement restricted stock unit (RSU) awards granted as an employment inducement under Nasdaq Listing Rule 5635(c)(4). On December 19, 2025, the company granted RSUs to 39 new employees totaling 80,425 shares under the 2025 Inducement Equity Incentive Plan. The RSUs vest over four years: 25% at the first anniversary of each vesting commencement date and then 1/16th each quarter, subject to continued service. CareDx provided the disclosure to comply with Nasdaq rule requirements.
CareDx (Nasdaq: CDNA) announced the third SHORE manuscript published in the Journal of Heart and Lung Transplantation on November 24, 2025, reporting prognostic value for HeartCare® molecular testing in heart transplant recipients.
The study of 1,934 patients across 59 centers found that positive HeartCare results (both AlloMap and AlloSure Heart) at 2–6 months post‑transplant were linked to a nearly twofold higher one‑year cumulative incidence of graft dysfunction and cardiovascular death (15.5% vs. 8.5% or lower; p=0.009). A positive HeartCare result at any time (2 months–5 years) was associated with a threefold increase in 30‑day risk of those outcomes. Elevated molecular signals identified risk even when biopsies were normal, supporting HeartCare's independent prognostic role.
CareDx (Nasdaq: CDNA) will participate in two investor conferences in late 2025: a Fireside Chat at the Stephens Investment Conference in Nashville on Wednesday, November 19, 2025 at 8:00 AM CT, and a presentation at the Piper Sandler Healthcare Conference in New York on Wednesday, December 3, 2025 at 4:30 PM ET.
Live and archived webcasts of both presentations will be available in the Events and Presentations section of CareDx investor relations at investors.caredx.com.
CareDx (Nasdaq: CDNA) announced inducement equity awards on November 4, 2025 under its 2025 Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The company granted restricted stock units (RSUs) to 49 new employees totaling 113,250 shares and separately granted 88,180 RSUs to Dr. Jeffrey Teuteberg upon his appointment as Chief Medical Officer. The RSUs vest over four years: 25% on the first anniversary of each recipient’s vesting commencement date and thereafter 1/16th each quarter, subject to continued service.
CareDx (Nasdaq: CDNA) announced new kidney transplant molecular data and the launch of HistoMap Kidney, a tissue-based gene expression assay that complements pathology to characterize rejection phenotypes.
Key scientific presentations at ASN Kidney Week 2025 (Nov 6–8) included AlloView/AlloSure Plus performance for predicting antibody-mediated rejection, a 54-patient study finding donor kidney volume did not affect AlloSure levels or 1-year graft function, and results showing AlloSure plus blood gene expression profiling are usable for rejection screening from week 1 post-transplant. HistoMap Kidney will be available early 2026 via a clinical study.
CareDx (Nasdaq: CDNA) reported Q3 2025 revenue of $100.1M, up 21% year‑over‑year, driven by testing services revenue of $72.2M (+19%) and testing volume of ~50,300 samples (+13%). GAAP net income was $1.7M versus a GAAP loss of $10.6M in Q3 2024; adjusted EBITDA was $15.3M versus $6.9M a year earlier. Cash, cash equivalents and marketable securities totaled $194.2M as of September 30, 2025, net of a $25.6M share repurchase; no debt outstanding. The company raised full‑year 2025 revenue guidance to $372M–$376M and adjusted EBITDA guidance to $35M–$39M.
CareDx (Nasdaq: CDNA) announced the appointment of Jeffrey John Teuteberg, MD as Chief Medical Officer, effective October 1, 2025. Dr. Teuteberg brings more than two decades of clinical transplantation experience, including senior roles at Stanford and University of Pittsburgh Medical Center, board certification in Heart Failure/Cardiac Transplantation, and prior service as President of ISHLT.
He will lead CareDx’s global Medical Affairs, including Medical Directors, Medical Science Liaisons, and clinical research operations, and has served as principal investigator of the SHORE study on noninvasive rejection surveillance.
CareDx (Nasdaq: CDNA) published the second SHORE study in Journal of the American College of Cardiology: Heart Failure on October 23, 2025, reporting the largest prospective analysis of antibody-mediated rejection (AMR) in heart transplantation.
The study covered 2,240 patients across 59 U.S. centers, analysing 24,768 biopsies, 8,851 paired AlloSure Heart dd-cfDNA samples, and 136 AMR-positive biopsies paired with dd-cfDNA. AlloSure Heart ≥0.50% showed 92.8% specificity for AMR. Results supported context-dependent AlloSure thresholds to reduce unnecessary biopsies and showed AlloSure declines after presumed AMR treatment, indicating response monitoring utility.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
